Perkins Capital Management Inc. Boosts Stock Holdings in Cryoport, Inc. (NASDAQ:CYRX)

Perkins Capital Management Inc. boosted its position in Cryoport, Inc. (NASDAQ:CYRX - Free Report) by 1,286.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 159,400 shares of the company's stock after purchasing an additional 147,900 shares during the quarter. Perkins Capital Management Inc. owned about 0.32% of Cryoport worth $1,240,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Thematics Asset Management increased its holdings in shares of Cryoport by 176.2% during the third quarter. Thematics Asset Management now owns 1,705,000 shares of the company's stock worth $13,828,000 after purchasing an additional 1,087,800 shares during the period. Fred Alger Management LLC increased its position in shares of Cryoport by 49.9% during the 3rd quarter. Fred Alger Management LLC now owns 2,698,768 shares of the company's stock valued at $21,887,000 after purchasing an additional 898,481 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in shares of Cryoport during the 3rd quarter worth $3,405,000. LPL Financial LLC boosted its holdings in shares of Cryoport by 1,366.1% in the 4th quarter. LPL Financial LLC now owns 436,766 shares of the company's stock worth $3,398,000 after buying an additional 406,976 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its position in Cryoport by 1,464.4% during the third quarter. JPMorgan Chase & Co. now owns 305,237 shares of the company's stock valued at $2,475,000 after buying an additional 285,726 shares during the period. 92.90% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Insider Activity at Cryoport

In other news, CEO Jerrell Shelton sold 4,620 shares of the stock in a transaction on Monday, March 17th. The shares were sold at an average price of $6.29, for a total value of $29,059.80. Following the transaction, the chief executive officer now owns 765,399 shares of the company's stock, valued at $4,814,359.71. This represents a 0.60 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have sold 19,830 shares of company stock valued at $118,353 over the last three months. 10.10% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on CYRX. Needham & Company LLC reiterated a "buy" rating and issued a $11.00 price objective on shares of Cryoport in a research note on Wednesday, March 5th. Guggenheim initiated coverage on Cryoport in a research report on Thursday, December 19th. They issued a "buy" rating and a $11.00 price target for the company. Finally, UBS Group raised Cryoport from a "neutral" rating to a "buy" rating and set a $10.00 price objective on the stock in a report on Monday. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $11.67.

Cryoport Price Performance

Shares of CYRX stock traded down $0.15 on Friday, reaching $6.09. The company's stock had a trading volume of 272,866 shares, compared to its average volume of 534,492. The company has a market capitalization of $303.95 million, a P/E ratio of -1.80 and a beta of 1.67. Cryoport, Inc. has a 12-month low of $4.58 and a 12-month high of $20.11. The stock's 50 day simple moving average is $6.68 and its 200-day simple moving average is $7.32. The company has a quick ratio of 5.32, a current ratio of 5.70 and a debt-to-equity ratio of 0.48.

Cryoport (NASDAQ:CYRX - Get Free Report) last announced its earnings results on Tuesday, March 4th. The company reported ($0.42) earnings per share for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.09). Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. The business had revenue of $59.53 million during the quarter, compared to the consensus estimate of $58.71 million. During the same quarter in the prior year, the company earned ($0.29) earnings per share. As a group, equities analysts predict that Cryoport, Inc. will post -0.99 earnings per share for the current fiscal year.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.